Supermax Corporation Bhd (7106) Fair Value & Analysis
Healthcare · MY · Market cap 795M MYR
Risks
Fair value as of: Aug 13, 2026
From 1 valuation models · updated 12 days ago
Share price +14.8% over the past month.
Below-average quality, currently priced close to our fair value.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- A fairly wide model range (0.2100 MYR to 0.4000 MYR) leaves room in how you read the outcome.
- Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range 0.2500 MYR – 4.07 MYR · fair‑value band 0.2100 MYR – 0.4000 MYR · the 0.3100 MYR price screens below the 0.3200 MYR fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Supermax Corporation Bhd (7106) currently trades at 0.3100 MYR, while our model-based Fair Value estimate is 0.3200 MYR, implying the stock looks roughly 3.2% fairly valued today. The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.
Over the trailing twelve months, Supermax Corporation Bhd generated revenue of 672M MYR at a net margin of -42.5%. Revenue declined 37.8% year over year. It earns a return on equity of -7.2%. The balance sheet holds a net cash position of 718M MYR. Fundamentals as of Aug 13, 2026
Our scenario range runs from 0.2100 MYR (bear case) to 0.4000 MYR (bull case); at 0.3100 MYR, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 54% below its 52-week high and 24% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -46% fair-value upside, at 3%, 7106 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Notify me when 7106 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 41 · Market factors (momentum, volatility) 36
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Supermax Corporation Berhad, an investment holding company, manufactures, distributes, and markets medical gloves and contact lenses in Europe, North America, Central America, South America, Asia, Oceania, and Africa. It operates through four segments: Investment Holding, Manufacturing of Gloves, Trading of Gloves, and Others.
Full company description
Supermax Corporation Berhad, an investment holding company, manufactures, distributes, and markets medical gloves and contact lenses in Europe, North America, Central America, South America, Asia, Oceania, and Africa. It operates through four segments: Investment Holding, Manufacturing of Gloves, Trading of Gloves, and Others. The company offers various types of nitrile latex and natural rubber gloves, as well as personal protective equipment. It is also involved in the trading, importing, and distribution of latex gloves; generation of biomass energy; marketing and distribution of healthcare products and medical devices; manufactures and sells face masks; and property holding activities. The company sells its products to laboratories, pharmacists, hospitals, doctors, and surgeons under the SUPERMAX, AURELIA, and MAXTER brands. It also exports its products to approximately 165 countries. The company was founded in 1987 and is headquartered in Sungai Buloh, Malaysia.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2020 – FY2024 · reported fiscal years
Supermax Corporation Bhd reported revenue of 782M MYR in FY2024 versus 7.2B MYR in FY2020, a compound −42.5%/yr. Reported net income was −160M MYR in FY2024.
Watch 7106: get an alert when its fair value changes →
Peer Group
Medical Instruments & Supplies · 207 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $378.81 | $150.04 | -60% |
| EssilorLuxottica Société anonyme EL | €164.40 | €94.93 | -42% |
| Medline Inc MDLN | $35.50 | $30.15 | -15% |
| Becton, Dickinson and Company BDX | $182.09 | $100.46 | -45% |
| Alcon Inc ALC | $73.58 | $39.78 | -46% |
| ResMed Inc RMD | A$31.25 | A$26.33 | -16% |
| West Pharmaceutical Services, Inc WST | $352.29 | $141.58 | -60% |
| Sartorius Stedim Biotech S.A DIM | €180.30 | €48.88 | -73% |
| Straumann Holding STMN | CHF 102.05 | CHF 47.31 | -54% |
| Sartorius Aktiengesellschaft SRT3 | €236.00 | €63.30 | -73% |
Compare Supermax Corporation Bhd with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Discover undervalued stocks
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Supermax Corporation Bhd (7106) overvalued or undervalued?
What is the fair value of 7106?
What is the quality score of 7106?
What is the revenue of Supermax Corporation Bhd (7106)?
What is the net profit margin of 7106?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Supermax Corporation Bhd and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.